Shift toward genome-first testing proposed to reduce rare disease diagnostic delays

The diagnostic process for rare diseases often spans years, creating a significant economic burden for families and healthcare systems. Baylor Genetics estimates that the average diagnostic odyssey costs over $220,000 in avoidable medical expenses and lost income, driven by repetitive testing and specialist bottlenecks.

Baylor Genetics CEO Kengo Takishima advocates for a genome-first approach, where whole genome sequencing (WGS) is utilized as a primary diagnostic tool rather than a final option. According to Takishima, this shift could streamline workflows and prevent the accumulation of costs associated with uninformative procedures.

Data suggests that early WGS intervention can lead to substantial savings. For instance, in acute care settings, rapid whole genome sequencing (rWGS) has been linked to potential multi-million dollar reductions in inpatient payments by shortening hospital stays and accelerating clinical decision-making.

As the medical field continues to face resource constraints, the reliance on sequential, outdated testing models is increasingly under scrutiny. Moving toward comprehensive genomic analysis at the start of the diagnostic process is being presented as a necessary evolution to improve clinical efficiency and patient care quality.